Cellares, a pioneering force in cell therapy manufacturing, has announced a successful $255 million Series C funding round. The funds will be channeled towards the launch of the world’s first commercial-scale Integrated Development and Manufacturing Organization (IDMO) Smart Factory.
Key Highlights
- The funding round was spearheaded by Koch Disruptive Technologies and saw participation from global biopharmaceutical giant Bristol Myers Squibb, DFJ Growth, Willett Advisors, and other existing investors like Eclipse, Decheng Capital, and 8VC.
- The IDMO Smart Factory, with its advanced robotics, interconnected software, and purpose-built technology, aims to produce 40,000 cell therapy batches annually.
Source: PR Newswire
Notable Quotes
- “Cell therapies have tremendous curative potential across a wide range of diseases. But right now, manufacturing by conventional CDMOs is expensive, failure-prone, and impossible to scale,” – David Mauney, Managing Director of Koch Disruptive Technologies
- “The creation of the first IDMO marks the beginning of a new era, in which cell therapies will finally be able to reach patients in need,” – Fabian Gerlinghaus, CEO of Cellares
SoH's Take
- Innovative Leap in Cell Therapy Manufacturing: Cellares’ decision to introduce the first IDMO Smart Factory is a monumental stride in the cell therapy manufacturing domain. This move not only reflects their commitment to innovation but also their vision to cater to the burgeoning global demand for cell therapies.
- Potential Market Disruption: With the capability to produce up to 40,000 cell therapy batches annually, Cellares is poised to disrupt the market. Their integrated approach, combining advanced robotics with interconnected software, could set a new industry standard.
